tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results
PremiumMarket NewsAcrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results
8d ago
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data
Premium
Company Announcements
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data
8d ago
Acrivon Therapeutics announces progress across pipeline
Premium
The Fly
Acrivon Therapeutics announces progress across pipeline
8d ago
Positive Outlook and Buy Rating for Acrivon Therapeutics, Inc. Based on Promising Clinical Data and Strategic Advancements
PremiumRatingsPositive Outlook and Buy Rating for Acrivon Therapeutics, Inc. Based on Promising Clinical Data and Strategic Advancements
2M ago
Acrivon Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
Acrivon Therapeutics Reports Q3 2025 Financial Results
2M ago
Acrivon Therapeutics reports Q3 EPS (47c), consensus (58c)
Premium
The Fly
Acrivon Therapeutics reports Q3 EPS (47c), consensus (58c)
2M ago
Acrivon Therapeutics, Inc.: Promising Clinical Developments and Strong Financial Position Justify Buy Rating
PremiumRatingsAcrivon Therapeutics, Inc.: Promising Clinical Developments and Strong Financial Position Justify Buy Rating
5M ago
Acrivon Therapeutics price target lowered to $8 from $9 at Oppenheimer
Premium
The Fly
Acrivon Therapeutics price target lowered to $8 from $9 at Oppenheimer
5M ago
Acrivon Therapeutics, Inc. Receives Buy Rating Due to Promising Clinical Data and Strategic Trial Expansion
Premium
Ratings
Acrivon Therapeutics, Inc. Receives Buy Rating Due to Promising Clinical Data and Strategic Trial Expansion
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100